webinar register page

Topic

Real-world impact of bioengineering: A webinar from Nature Reviews Bioengineering

Description

Nature Reviews Bioengineering is one of the latest journals to be joining the Nature Portfolio in 2023. It will be a monthly, online-only journal publishing authoritative, accessible and agenda-setting Reviews, Perspectives and Comments covering the full breadth of bioengineering, with a focus on translation and the engineering of solutions for real-world applications.

Join the Chief Editor of Nature Reviews Bioengineering, Christine Horejs, and two esteemed panelists in the field of Bioengineering, Robert Langer and Annie Moisan, as they discuss the real-world impact of Bioengineering and the role this new journal will play in supporting scientists at all career stages with their research.

This webinar is designed to be an introduction to the new journal for librarians, editors, researchers, and information managers across the university and corporate sectors. The panel discussion will be followed by a lively Q&A where participants will have the chance to ask questions directly to our panelists.

Not able to attend this session? Register anyway to receive a recording of the event afterwards.

Time

Nov 28, 2022 03:15 PM in Amsterdam, Berlin, Rome, Stockholm, Vienna

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Springer Nature Events.

All fields are required

Your Information
Send to
Message preview	Hi there, You are invited to a Zoom webinar. When: Nov 28, 2022 03:15 PM Amsterdam, Berlin, Rome, Stockholm, Vienna Topic: Real-world impact of bioengineering: A webinar from Nature Reviews Bioengineering Register in advance for this webinar: https://us06web.zoom.us/webinar/register/WN_B1QxXb1nRb-uMMuvpZOs8g After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers Professor Robert Langer (David H. Koch Institute Professor @Massachusetts Institute of Technology) Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology; being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written over 1,500 articles, which have been cited over 374,000 times; his h-index of 304 is the highest of any engineer in history and the 2nd highest of any individual in any field. His patents have licensed or sublicensed to over 400 companies; he is a cofounder of a number of companies including Moderna. Dr Langer served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the US National Medal of Science and the US National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Science, Kyoto Prize... Annie Moisan (Program Director HOPE - Human Organs, Physiology & Engineering @Wellcome Leap) As the HOPE Program Director at Wellcome Leap, Annie leads multidisciplinary teams that aim at delivering scientific breakthroughs in human health by leveraging on human models that recreate tissue function and immune competency at an unprecedented level of fidelity. HOPE requires the coordinated and synergistic work of academic labs and biopharma partners to demonstrate the translational value of a next generation of bioengineered models as predictive platforms for drug development and universal supply of transplantable organs. Prior to Leap, Annie worked for 10 years in the pharmaceutical industry where she developed and applied advanced human cell models for phenotypic drug screening and mechanistic understanding of drug-mediated toxicity. She pioneered implementation of microphysiological systems (MPS) such as organs-on-chip in the industry setting (Roche Innovation Center Basel), by establishing and leading collaborations with academic institutions, start-ups & biopharma partners. Christine Horejs (Chief Editor @Nature Reviews Bioengineering) Christine started at Springer Nature in 2017 as an editor for Nature Reviews Materials, where she handled the topics of biomaterials, nanomedicine and bioengineering. From July 2019, she moved to be a locum senior editor at Nature Nanotechnology, where she was primarily responsible for the areas of nanomedicine and nanobiotechnology. In January 2021, she became chief editor of Nature Reviews Materials, and since January 2022, she has been heading the launch of Nature Reviews Bioengineering. Christine has an MSci and PhD in nanobiotechnology from the University of Natural Resources and Life Sciences, Vienna, Austria. She did her postdoc in the lab of Molly Stevens at Imperial College London, UK, investigating the extracellular matrix and cell–material interactions, and she conducted research at the Karolinska Institute, Sweden, where she studied anti-fibrotic biomaterials in vivo. Christine is based in Berlin, Germany.

Time Zone:

webinar register page

Share via Email

Switch Time Zone

Upcoming Meetings